Abstract 380P
Background
Globally, there are roughly 476 million indigenous peoples in 90 nations worldwide, representing a wide range of cultures, dialects, and spirits. India has the world's second-highest concentration of tribal people after African countries. Spread across 705 tribes accounting for 8.6% of the country’s population, over 104 million tribal people live; making India home to numerous tribes with diverse origins, customs, and societal practices. Government of India have identified Primitive tribal communities on the basis of their pre-agricultural level of technology, extremely low level of literacy, and small, stagnant, or diminishing population. This epidemiological cross- sectional study was designed to assess the prevalence of oral cancer and its awareness among Irula tribes of South India.
Methods
A cross sectional descriptive study was conducted among 200 Irula tribes using a pretested Questionnaire, which included demographic information, tobacco habits, its frequency, and cancer awareness. Oral examination to assess oral cancer was done by a single examiner. SPSS version 21 was used to analyse the collected data.
Results
The findings revealed that 87% of the 200 study participants had no formal education and 38% had never visited a dentist. 64.5% practised indigenous brushing. There were 52% of oral mucosal lesions and 6% of malignant oral tumours found. This community had a very high prevalence of periodontal disease, tobacco chewing, and deeply ingrained beliefs and customs about dentition and dental treatment. The prevalence of oral mucosal lesions in the study population was due to tobacco use and a lack of knowledge about the harmful effects of the products used.
Conclusions
Although the problems associated with smoking and chewing tobacco are extensively documented in the literature, it is worrying that this indigenous group is not aware of the consequences. The public should be made aware of these concerns, especially those in high-risk groups, according to health specialists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract